It Is High Time for a Renaissance in the UK Cannabis Industry
Written for Business of Cannabis by Andrew Pepper, Partner at business restructuring and consultancy firm ReSolve Advisory. In January
Written for Business of Cannabis by Andrew Pepper, Partner at business restructuring and consultancy firm ReSolve Advisory. In January
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has announced plans to launch a Phase 1 clinical trial into a
MGC Pharmaceuticals / Argent BioPharma MGC Pharmaceuticals has become the latest UK-listed cannabis company to opt for a rebrand
Cellular Goods (Cel AI) Cellular Goods has this morning announced another major pivot in its strategy, just days after
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, is pleased to announce that dosing of
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I
The UK’s National Health Service (NHS) Research Ethics Committee this week approved the full-scale rollout of a new clinical trial
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies announced this week that it had identified a potential ‘first in class’ immunotherapy
OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified
Oxford Cannabinoid Technologies The London Stock Exchange listed pharmaceutical cannabis company announced yesterday that it has at last
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
© 2023 Prohibition Holdings Ltd. All Rights Reserved.